Are We Targeting the Right Metric for Heart Failure? Comparison of Hospital 30-day Readmission Rates and Total Episode of Care Inpatient Days
Overview
Authors
Affiliations
Background: Hospitals are challenged to reduce length of stay (LOS), yet simultaneously reduce readmissions for patients with heart failure (HF). This study investigates whether 30-day rehospitalization or an alternative measure of total inpatient days over an episode of care (EOC) is the best indicator of resource use, HF quality, and outcomes.
Methods: Using data from the American Heart Association's Get With The Guidelines-Heart Failure Registry linked to Medicare claims, we ranked and compared hospitals by LOS, 30-day readmission rate, and overall EOC metric, defined as all hospital days for an HF admission and any subsequent admissions within 30 days. We divided hospitals into quartiles by 30-day EOC and 30-day readmission rates. We compared performance by EOC and readmission rate quartiles with respect to quality of care indicators and 30-day postdischarge mortality.
Results: The population had a mean age of 80 ± 7.95 years, 45% were male, and 82% were white. Hospital-level unadjusted median index LOS and overall EOC were 4.9 (4.2-5.6) and 6.2 (5.3-7.4) days, respectively. Median 30-day readmission rate was 23.2%. Hospital HF readmission rate was not associated with initial hospital LOS, only slightly associated with total EOC rank (r = 0.26, P = .001), and inversely related to HF performance measures. After adjustment, there was no association between 30-day readmission and decreased 30-day mortality. In contrast, better performance on the EOC metric was associated with decreased odds of 30-day mortality.
Conclusions: Although hospital 30-day readmission rate was poorly correlated with LOS, quality measures, and 30-day mortality, better performance on the EOC metric was associated with better 30-day survival. Total inpatient days during a 30-day EOC may more accurately reflect overall resource use and better serve as a target for quality improvement efforts.
Namvar M, Fakhrolmobasheri M, Mazaheri-Tehrani S, Heidarpour M, Emamimeybodi M, Shafie D Emerg Med Int. 2023; 2023:6338597.
PMID: 36923467 PMC: 10010878. DOI: 10.1155/2023/6338597.
Rosano G, Vitale C, Adamo M, Metra M J Cardiovasc Med (Hagerstown). 2021; 23(3):149-156.
PMID: 34937849 PMC: 10484190. DOI: 10.2459/JCM.0000000000001221.
Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review.
Abdelnabi M, Saleh Y, Almaghraby A, Girgis H, Gerges F Curr Cardiol Rev. 2021; 18(3):e310821195982.
PMID: 34488614 PMC: 9615216. DOI: 10.2174/1573403X17666210831142452.
Givertz M, Yang M, Hess G, Zhao B, Rai A, Butler J ESC Heart Fail. 2021; 8(3):1915-1923.
PMID: 33689217 PMC: 8120411. DOI: 10.1002/ehf2.13155.
Virani S, Zieroth S, Bray S, Ducharme A, Harkness K, Koshman S CJC Open. 2020; 2(3):151-160.
PMID: 32462129 PMC: 7242502. DOI: 10.1016/j.cjco.2020.03.001.